Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

Brain

Volumn 138, Issue 12, 2015, Pages 3747-3759

  Jack, Clifford R ^a   Wiste, Heather J ^a   Weigand, Stephen D ^a   Knopman, David S ^a   Mielke, Michelle M ^a   Vemuri, Prashanthi ^a   Lowe, Val ^a   Senjem, Matthew L ^a   Gunter, Jeffrey L ^a   Reyes, Denise ^a   Machulda, Mary M ^a   Roberts, Rosebud ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; amyloid and neurodegeneration; amyloid imaging; cognitive ageing; preclinical Alzheimer's disease

Indexed keywords

APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BRAIN REGION; BRAIN SIZE; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; FUNCTIONAL STATUS; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; NERVE DEGENERATION; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VERY ELDERLY; BRAIN CORTEX; FUNCTIONAL NEUROIMAGING; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOIDOSIS; BIOMARKERS; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; FEMALE; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84951033618     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv283     Document Type: Article

References (71)

1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimers disease: recommendations from the National Institute on Aging and Alzheimers Association Workgroup. Alzheimers Dement 2011; 7: 270-9.
2. Alexopoulos P, Kriett L, Haller B, Klupp E, Gray K, Grimmer T, et al. Limited agreement between biomarkers of neuronal injury at different stages of Alzheimers disease. Alzheimers Dement 2014; 10: 684-9.
3. Barkhof F, Polvikoski TM, van Straaten EC, Kalaria RN, Sulkava R, Aronen HJ, et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69: 1521-7.
4. Barnes J, Ridgway GR, Bartlett J, Henley SM, Lehmann M, Hobbs N, et al. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage 2010;53: 1244-55.
5. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimers Disease. N Engl J Med 2012; 367: 795-804.
6. Benzinger TL, Blazey T, Jack CR, Jr., Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimers disease. Proc Natl Acad Sci USA 2013; 110: E4502-9.
7. Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression. Neurology 2015; 84: 508-15.
8. Chetelat G. Alzheimer disease: a beta-independent processes-rethinking preclinical AD. Nat Rev Neurol 2013; 9: 123-4.
9. Chetelat G, Desgranges B, Landeau B, Mezenge F, Poline JB, de la Sayette V, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimers disease. Brain 2008; 131(Pt 1): 60-71.
10. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-24.
11. Curiati PK, Tamashiro-Duran JH, Duran FL, Buchpiguel CA, Squarzoni P, Romano DC, et al. Age-related metabolic profiles in cognitively healthy elders: results from a voxel-based [18F]fluorodeoxyglucose-positron-emission tomography study with partial volume effects correction. AJNR Am J Neuroradiol 2011; 32: 560-5.
12. Davatzikos C, Fan Y, Wu X, Shen D, Resnick SM. Detection of prodromal Alzheimers disease via pattern classification of magnetic resonance imaging. Neurobiol Aging 2008; 29: 514-23.
13. DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging 2005; 26: 491-510.
14. Di Paola M, Caltagirone C, Fadda L, Sabatini U, Serra L, Carlesimo GA. Hippocampal atrophy is the critical brain change in patients with hypoxic amnesia. Hippocampus 2008; 18: 719-28.
15. Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, et al. The cortical signature of Alzheimers disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloidpositive individuals. Cereb Cortex 2009; 19: 497-510.
16. Duara R, Loewenstein DA, Shen Q, Barker W, Potter E, Varon D, et al. Amyloid positron emission tomography with (18)F-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimers disease. Alzheimers Dement 2013; 9: 295-301.
17. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimers disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-29.
18. Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL, et al. Longitudinal Change in CSF biomarkers in autosomaldominant Alzheimers disease. Sci Transl Med 2014; 6: 226ra30.
19. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. Brain changes in older adults at very low risk for Alzheimers disease. J Neurosci 2013; 33: 8237-42.
20. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer Disease kindred: a cross-sectional study. JAMA Neurol 2015; 72: 316-24.
21. Frisoni GB, Fox NC, Jack CR, Jr., Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010; 6: 67-77.
22. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimers disease. Nature 1991; 349: 704-6.
23. Jack CR, Jr., Albert MS, Knopman DS, McKhann GM, Sperling RA, Carillo M, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011a; 7: 257-62.
24. Jack CR, Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, OBrien PC, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002; 58: 750-7.
25. Jack CR, Jr, Holtzman DM. Biomarker modeling of Alzheimers disease. Neuron 2013; 80: 1347-58.
26. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013a; 12: 207-16.
27. Jack CR, Jr., Knopman DS, Weigand SD, Wiste HJ, vemuri P, Lowe V, et al. An operational approach to NIA-AA crtiteria for preclinical Alzheimers disease. Ann Neurol 2012; 71: 765-75.
28. Jack CR, Jr., Theodore WH, Cook M, McCarthy G. MRI-based hippocampal volumetrics: data acquisition, normal ranges, and optimal protocol. Magn Reson Imaging 1995; 13: 1057-64.
29. Jack CR, Jr., Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology 1989; 172: 549-54.
30. Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for Ordering of Alzheimer Disease biomarkers. Arch Neurol 2011b; 68: 1526-35.
31. Jack CR, Jr., Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014a; 82: 1605-12.
32. Jack CR, Jr., Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013b; 81: 1732-40.
33. Jack CR, Jr., Wiste HJ, Weigand SD, Knopman DS, Vemuri P, Mielke MM, et al. Age, Sex, and APOE epsilon4 effects on memory, brain structure, and beta-amyloid across the adult life span. JAMA Neurol 2015;72: 511-9.
34. Jack CR, Jr, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral betaamyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol 2014b; 13: 997-1005.
35. Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 2013; 77: 219-34.
36. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73: 1193-9.
37. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015; 313: 1924-38.
38. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimers disease and age-related cognitive decline. Nature 2012; 488: 96-9.
39. Josephs KA, Duffy JR, Fossett TR, Strand EA, Claassen DO, Whitwell JL, et al. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. Arch Neurol 2010; 67: 596-605.
40. Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimers disease. Acta Neuropathol 2014; 127: 811-24.
41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19.
42. Klunk WE, Koeppe RA, Price JC, Benzinger T, Devous M, Jagust W, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Demen 2015; 11: 1-15.
43. Knopman DS, Jack CR, Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe V, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012; 78: 1576-82.
44. Knopman DS, Jack CR, Jr., Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Brain injury biomarkers are not dependent on betaamyloid in normal elderly. Ann Neurol 2013; 73: 472-80.
45. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207-18.
46. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimers disease locus. Science 1995; 269: 973-7.
47. Lowe VJ, Kemp BJ, Jack CR, Jr., Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009; 50: 878-86.
48. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimers disease: Recommendations from the National Institute on Aging and the Alzheimers Assocation Workgroup. Alzheimers Dement 2011; 7: 263-9.
49. Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, et al. Synergistic effect of beta-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol 2014a; 71: 1379-85.
50. Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology 2014b; 82: 1760-7.
51. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimers disease spectrum. Brain 2015; 138(Pt 5): 1370-81.
52. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Criteria for mild cognitive impairment due to alzheimers disease in the community. Ann Neurol 2013; 74: 199-208.
53. Prestia A, Caroli A, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, et al. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013; 80: 1048-56.
54. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, et al. The Mayo Clinic study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008; 30: 58-69.
55. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR, Jr. Comparison of different methodological implementations of voxelbased morphometry in neurodegenerative disease. Neuroimage 2005; 26: 600-8.
56. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, et al. Cloning of a gene bearing missense mutations in earlyonset familial Alzheimers disease. Nature 1995; 375: 754-60.
57. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Assocation workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011; 7: 280-92.
58. Su Y, Blazey TM, Snyder AZ, Raichle ME, Marcus DS, Ances BM, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 2015; 107: 55-64.
59. Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, et al. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun 2014; 2: 26.
60. Tsitsopoulos PP, Marklund N. Amyloid-beta peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol 2013; 4: 79.
61. van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, et al. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology 2013; 81: 1409-16.
62. Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS, et al. Alzheimers disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008a; 39: 1186-97.
63. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, et al. Antemortem MRI based Structural abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage 2008b; 42: 559-67.
64. Villain N, Fouquet M, Baron JC, Mezenge F, Landeau B, de La Sayette V, et al. Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimers disease. Brain 2010; 133: 3301-14.
65. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
66. Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimers disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013; 12: 957-65.
67. Whitwell JL, Jack CR, Jr., Parisi JE, Senjem ML, Knopman DS, Boeve BF, et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? Neurology 2010; 75: 2212-20.
68. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 2008; 71: 743-9.
69. Winkler AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage 2010; 53: 1135-46.
70. Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimers disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci 2013a; 33: 5553-63.
71. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, et al. Associations between Alzheimer Disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 2013b; 70: 1512-9.